NEW YORK (TheStreet) -- Shares of VIVUS  (VVUS - Get Report) rose 12.92% to $4.38 in morning trading Thursday after the FDA approved the company's erectile dysfunction drug Stendra.

The drug cuts in half the time necessary between taking the pill and engaging in sexual activity. Stendra is the first FDA-approved oral erectile dysfunction drug that one can take approximately 15 minutes before sexual activity. Viagra, Pfizer's  (PFE - Get Report) famous blue pill, can be taken an hour prior to sex.

Vivus developed the drug with Auxilium Pharmaceuticals (AUXL) , which is currently mulling a takeover offer from Endo International (ENDP - Get Report) .

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More than 11 million shares had changed hands as of 10:17 a.m., compared to the average volume of 1,462,930.

VVUS Chart VVUS data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.